1. Home
  2. CAPR vs LILAK Comparison

CAPR vs LILAK Comparison

Compare CAPR & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$19.50

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Liberty Latin America Ltd. Class C

LILAK

Liberty Latin America Ltd. Class C

HOLD

Current Price

$7.31

Market Cap

1.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAPR
LILAK
Founded
2005
2017
Country
United States
Bermuda
Employees
N/A
9000
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Cable & Other Pay Television Services
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
CAPR
LILAK
Price
$19.50
$7.31
Analyst Decision
Strong Buy
Hold
Analyst Count
8
1
Target Price
$44.63
$8.20
AVG Volume (30 Days)
1.7M
2.3M
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
$3.31
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.30
$4.75
52 Week High
$40.37
$9.13

Technical Indicators

Market Signals
Indicator
CAPR
LILAK
Relative Strength Index (RSI) 28.96 49.35
Support Level $5.25 $6.85
Resistance Level $30.39 $8.21
Average True Range (ATR) 1.33 0.31
MACD -0.26 0.03
Stochastic Oscillator 16.93 34.65

Price Performance

Historical Comparison
CAPR
LILAK

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About LILAK Liberty Latin America Ltd. Class C

Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.

Share on Social Networks: